Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   MYLAN
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-23
MYLAN
Dec-18
ALKEM LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,6253,979-   
Low Rs2,8352,190-   
Sales per share (Unadj.) Rs970.11,830.9-  
Earnings per share (Unadj.) Rs84.249.7-  
Cash flow per share (Unadj.) Rs110.2392.5-  
Dividends per share (Unadj.) Rs50.000-  
Avg Dividend yield %1.50-  
Book value per share (Unadj.) Rs756.41,980.7-  
Shares outstanding (eoy) m119.57514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.31.7 197.6%   
Avg P/E ratio x38.462.0 61.8%  
P/CF ratio (eoy) x29.37.9 373.1%  
Price / Book Value ratio x4.31.6 274.2%  
Dividend payout %59.40-   
Avg Mkt Cap Rs m386,2071,586,960 24.3%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m21,3140-   
Avg. sales/employee Rs Th026,913.6-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.8-  
INCOME DATA
Net Sales Rs m115,993941,976 12.3%  
Other income Rs m2,1610-   
Total revenues Rs m118,153941,976 12.5%   
Gross profit Rs m15,065243,748 6.2%  
Depreciation Rs m3,104176,375 1.8%   
Interest Rs m1,07445,306 2.4%   
Profit before tax Rs m13,04822,068 59.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,980-3,511 -84.9%   
Profit after tax Rs m10,06825,579 39.4%  
Gross profit margin %13.025.9 50.2%  
Effective tax rate %22.8-15.9 -143.5%   
Net profit margin %8.72.7 319.7%  
BALANCE SHEET DATA
Current assets Rs m86,064525,998 16.4%   
Current liabilities Rs m37,071383,511 9.7%   
Net working cap to sales %42.215.1 279.2%  
Current ratio x2.31.4 169.3%  
Inventory Days Days3384 39.0%  
Debtors Days Days6793 71.9%  
Net fixed assets Rs m37,245182,728 20.4%   
Share capital Rs m239502 47.7%   
"Free" reserves Rs m90,2080-   
Net worth Rs m90,4471,019,046 8.9%   
Long term debt Rs m01,099,877 0.0%   
Total assets Rs m124,5412,733,477 4.6%  
Interest coverage x13.21.5 884.5%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.90.3 270.3%   
Return on assets %8.92.6 345.0%  
Return on equity %11.12.5 443.5%  
Return on capital %15.63.2 491.0%  
Exports to sales %14.60-   
Imports to sales %00-   
Net fx Rs m12,7270-   
CASH FLOW
From Operations Rs m16,825195,743 8.6%  
From Investments Rs m1,128-101,177 -1.1%  
From Financial Activity Rs m-17,608-91,188 19.3%  
Net Cashflow Rs m4161,622 25.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.59 Rs / USD

Compare ALKEM LABORATORIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: WOCKHARDT  SAMRAT PHARMA  NORRIS MEDICINES  THEMIS MEDICARE  ANG LIFESCIENCES INDIA  



Today's Market

Gift Nifty Down 186 Points | Vodafone Idea to Roll Out 5G | Vedanta Issues Rupee-Denominated Bond | Top Buzzing Stocks Today Gift Nifty Down 186 Points | Vodafone Idea to Roll Out 5G | Vedanta Issues Rupee-Denominated Bond | Top Buzzing Stocks Today(Pre-Open)

Indian share markets Slipped further as the session progressed and ended the day weak.